MedTrace Logo

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

NCT01100463 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-10-08

No results posted yet for this study

Summary

The purpose of this research study is to see if combining uracil cream (UTC) with capecitabine (Xeloda) can prevent Hand-Foot Syndrome. The study will also see what effects UTC and capecitabine may have in patients with metastatic breast cancer.

Conditions

Interventions

DRUG

Cream

Twice daily lotion to prevent HFS

DRUG

0.1% Uracil Cream

Twice daily lotion to prevent HFS

Sponsors & Collaborators

  • Nanometics (d.b.a. PHD Biosciences)

    lead INDUSTRY

Principal Investigators

  • James Cantrell, MD · Birmingham Hematology/Oncology Associates

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01100463 on ClinicalTrials.gov